(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage epithelial ovarian, fallopian tube, and primary peritoneal cancers. Those included in the study … Continued
(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery. The two studies, EORTC and CHORUS, had a total of 1,220 participants whose median age was 63 years. Both studies included stage IIIC and stage IV … Continued
Holiday Greeting Cards that Give Back Send your friends and family customizable cards from Picaboo Cards for Causes and show your support for finding an ovarian cancer cure. The front of the card is all yours to customize! Be as creative as you want, with one photo or several, and choose from many card layouts, … Continued
#GivingTuesday is November 27th, and we need you to help us make a big impact! Please join us in #GivingTeal, for the 22,000 American women diagnosed with ovarian cancer every year, and the 200,000 living with this disease. Here’s how you can help. Facebook Fundraisers On November 27th, Facebook will match donations up to $7 … Continued
(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer. The incidence of ovarian cancer in all age groups in the study was similar to women with normal ovaries. While simple cysts do not … Continued
(November 13, 2018) The International Journal of Cancer recently published a study that explored the use of statins, which reduces one’s lipids, and their effect on ovarian cancer risk. After comparing a group of 2,040 women diagnosed with epithelial ovarian cancer to a group of 2,100 women without the disease, it was found that statins … Continued
(October 25, 2018) Through a series of surveys, interviews, and literature reviews the World Ovarian Cancer Coalition produced a report that detailed their findings and recommendations. Their study spanned the world, 44 countries, and collected responses from 1531 women. Of those women, all had been diagnosed with ovarian cancer on or after January 2013, and … Continued
(October 23, 2018) Olaparib, or Lynparza, was shown to increase progression-free survival (PFS) by almost three years in an ongoing trial known as SOLO-1. The women in the study are BRCA 1 or 2 positive and newly diagnosed with an advanced stage of high grade serous or endometroid ovarian cancer, primary peritoneal, or fallopian tube … Continued
(October 22, 2018) A team at the University of Illinois at Chicago, including OCRA grantee Matthew Dean, PhD, recently discovered the role that cancer cells have on their immediate environment. The research was funded in part by OCRA. More specifically, they found evidence that ovarian cancer cells formed in the fallopian tube change how the … Continued
(October 19, 2018) A retroactive study using SEER, or Surveillance, Epidemiology, and End Results, looked at the trends in ovarian cancer from 1983 to 2012. In almost 3 decades, the incidence of ovarian cancer per 100,000 fell from 13.7 to 10.8 and the median survival increased from 34 months to 52 months. When this survival … Continued
(October 18, 2018) Longtime OCRA Scientific Advisory Committee member and former grantee Kunle Odunsi, MD, PhD, has been elected to the National Academy of Medicine—a distinguished lifetime designation that is considered one of the highest honors in health and medicine. Members are elected by their peers based on their contributions to the advancement of the … Continued
(October 15, 2018) This month in Nature, researchers from Weill Cornell published a study that helps to explain why the body’s natural immune response struggles to fight back against ovarian cancer. Using ovarian tumors from humans and mice, they found that T cells, vital to destroying cancerous cells, are inhibited because of the tumor’s effect … Continued
Get email updates about research news, action alerts, and ways to join the fight.
